SWS Partners Has $1.11 Million Position in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• SWS Partners reduced its holdings in Vertex Pharmaceuticals by 24%, owning 2,482 shares worth approximately $1.11 million as of the last SEC filing.
• Director Bruce I. Sachs purchased 5,000 shares at an average price of $389.68, increasing his position by 12.5% and valuing his total holdings at around $17.54 million.
• The stock of Vertex Pharmaceuticals has a market cap of $98.90 billion and reported an earnings per share (EPS) of $4.52 for the last quarter, surpassing analysts' estimates.

SWS Partners reduced its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 24.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,482 shares of the pharmaceutical company's stock after selling 785 shares during the quarter. SWS Partners' holdings in Vertex Pharmaceuticals were worth $1,105,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in VRTX. Brighton Jones LLC grew its position in shares of Vertex Pharmaceuticals by 15.0% in the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company's stock valued at $1,783,000 after purchasing an additional 579 shares during the last quarter. Versant Capital Management Inc grew its position in Vertex Pharmaceuticals by 90.0% during the first quarter. Versant Capital Management Inc now owns 627 shares of the pharmaceutical company's stock worth $304,000 after buying an additional 297 shares in the last quarter. AdvisorNet Financial Inc grew its position in Vertex Pharmaceuticals by 8.6% during the first quarter. AdvisorNet Financial Inc now owns 1,473 shares of the pharmaceutical company's stock worth $714,000 after buying an additional 117 shares in the last quarter. Fifth Third Wealth Advisors LLC grew its position in Vertex Pharmaceuticals by 49.5% during the first quarter. Fifth Third Wealth Advisors LLC now owns 1,834 shares of the pharmaceutical company's stock worth $889,000 after buying an additional 607 shares in the last quarter. Finally, Rhumbline Advisers grew its position in Vertex Pharmaceuticals by 2.0% during the first quarter. Rhumbline Advisers now owns 451,031 shares of the pharmaceutical company's stock worth $218,669,000 after buying an additional 8,670 shares in the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Bruce I. Sachs bought 5,000 shares of the business's stock in a transaction dated Wednesday, August 6th. The stock was bought at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the purchase, the director owned 45,000 shares of the company's stock, valued at approximately $17,535,600. The trade was a 12.50% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Stock Up 1.0%

Shares of VRTX opened at $385.73 on Monday. The stock has a market cap of $98.90 billion, a price-to-earnings ratio of 27.57 and a beta of 0.44. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.88. The company has a 50-day moving average price of $406.00 and a two-hundred day moving average price of $445.87.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping analysts' consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The firm had revenue of $2.94 billion during the quarter, compared to analysts' expectations of $2.90 billion. During the same quarter last year, the company earned ($12.83) earnings per share. The company's revenue for the quarter was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Truist Financial set a $490.00 target price on Vertex Pharmaceuticals and gave the stock a "buy" rating in a research report on Tuesday, August 5th. Canaccord Genuity Group decreased their target price on Vertex Pharmaceuticals from $424.00 to $411.00 and set a "hold" rating on the stock in a research report on Wednesday, August 6th. Leerink Partnrs raised Vertex Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday. Stifel Nicolaus decreased their target price on Vertex Pharmaceuticals from $494.00 to $455.00 and set a "hold" rating on the stock in a research report on Tuesday, August 5th. Finally, UBS Group set a $553.00 price target on shares of Vertex Pharmaceuticals and gave the stock a "buy" rating in a research note on Tuesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $493.81.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.